As the global health community confronts the escalating threat of antibiotic resistance, advancing peptide-based immunomodulation through interdisciplinary collaboration and consistent investment will be key to unlocking the full therapeutic promise of AMPs, shaping a future of more effective infection control and improved tissue repair strategies. Here, ADSL is linked to infection.